Reference Library
Below is a reference list that includes an article describing the pivotal clinical trial and studies demonstrating the safety and efficacy of LUXÍQ® (betamethasone valerate) Foam, 0.12%, an article reviewing patient compliance with psoriasis medications, and an article comparing coverage areas of psoriasis medications.
  1. Feldman SR, Sangha N, Setaluri V. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol. 2000;42(6):1017-1020.

  2. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-632.

  3. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581-583.

THIS SITE IS INTENTED FOR U.S. AUDIENCES ONLY. For more information about LUXÍQ® Foam, contact your Physician or other Health Care Professional. Click here for Complete Product Information. Copyright ©2008 Stiefel Laboratories, Inc. All rights reserved. The use of and access to the information on this site are subject to the terms and conditions described under Legal Stuff on this web site. By using this site, you agree to the terms set forth therein. STIEFELCARE and STIEFELCARE and Design are service marks; RESEARCH IN DERMATOLOGY and the Foam Dollop Design are trademarks; and VERSAFOAM, the "V" Design, VERSAFOAM-HF, LUXÍQ, the Mousse Design, OLUX, STIEFEL, and STIEFEL and Design are registered trademarks of, Stiefel Laboratories, Inc.